The FDA Clears Keros Therapeutics' Investigational New Drug Application To Conduct A Phase 2 Trial Of KER-012 In Combination With Background Therapy In Patients With Pulmonary Arterial Hypertension
Portfolio Pulse from Benzinga Newsdesk
The FDA has approved Keros Therapeutics' Investigational New Drug Application, allowing the company to conduct a Phase 2 trial of KER-012 in combination with background therapy in patients with Pulmonary Arterial Hypertension.
July 24, 2023 | 12:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Keros Therapeutics has received FDA approval to conduct a Phase 2 trial of KER-012, which could potentially lead to a new treatment for Pulmonary Arterial Hypertension.
The FDA approval for the Phase 2 trial of KER-012 is a significant milestone for Keros Therapeutics. This could potentially lead to a new treatment for Pulmonary Arterial Hypertension, which would significantly boost the company's product portfolio and future revenue potential. Therefore, this news is likely to have a positive impact on KROS's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100